The ANCHOR trial (NCT03774654) and its follow-up ANCHOR2 (NCT05487651) are evaluating allogeneic CD19-targeting CAR-iNKTs in patients with relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin lymphoma (NHL) and acute/chronic lymphocytic leukemia (ALL/CLL). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.